Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News CytoMed Therapeutics Ltd GDTC

Healthcare Biotechnology
CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological... see more

Current News (NDAQ:GDTC)

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

GlobeNewswire 10 days ago

CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95%

GlobeNewswire October 22, 2025

CytoMed makes cash bid for potential acquisition of TC BioPharm Limited's relevant assets

GlobeNewswire October 14, 2025

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia 

GlobeNewswire October 2, 2025

Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition

GlobeNewswire August 28, 2025

CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

GlobeNewswire August 18, 2025

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

GlobeNewswire July 21, 2025

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

GlobeNewswire April 28, 2025

CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

GlobeNewswire February 6, 2025
View More News ››

Opinion & Analysis (NDAQ:GDTC)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GDTC)

Interesting

Interesting development they have here. The IPO was a success. Watching this deal closely. 
Chart1 - November 3, 2023
View more Bullboard ››

Globex Mining Enterprises Inc.

Globex Mining Enterprises Inc.

Globex Mining Enterprises Inc. is a Canada-based company, which is focused on exploration and development of a property bank ...
View More »